During his time at the NCI, Dr. Joseph Kim was involved in clinical development of novel immunotherapies, such as therapeutic cancer vaccines and immune checkpoint inhibitors, for prostate cancer and other solid tumors. He is also a recipient of several awards, including Young Investigator Award by Conquer Cancer Foundation, American Society of Clinical Oncology (ASCO). His research interests are in early drug development, particularly immunotherapies for genitourinary cancers and others, as well as in development of biomarkers to predict responses to immunotherapy and those to identify aggressive prostate cancers at high risk of recurrence and progression. He is an active member of Society of Immunotherapy of Cancer and ASCO. His clinical interest is in care of patients with prostate cancer at various stages, muscle invasive bladder cancer and those with metastatic disease.